Vytrus Biotech SA
Vytrus Biotech SA provides industrial services focused on environmental solutions, including waste management and pollution control technologies.
Business. Vytrus Biotech SA (VYT.MC) is a company operating in the Environmental Services & Equipment industry within the broader Industrials sector. The firm is headquartered in Spain and is primarily listed on the Madrid Stock Exchange (BME). Specific details regarding its operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Vytrus Biotech SA (VYT.MC) is a company operating in the Environmental Services & Equipment industry within the broader Industrials sector. The firm is headquartered in Spain and is primarily listed on the Madrid Stock Exchange (BME). Specific details regarding its operating segments and geographic revenue mix are not available.
Vytrus Biotech maintains a strong liquidity position, with a current ratio of 3.03 and cash and equivalents of EUR 1.5 million, indicating the company can easily cover its short-term obligations. The company's liquidity risk is assessed as low, supported by its robust cash flow generation, with operating cash flow of EUR 3.9 million and free cash flow of EUR 1.19 million.
Profitability metrics show Vytrus Biotech is performing well above industry norms. The company's return on equity (ROE) of 28.1% and return on assets (ROA) of 19.75% are strong indicators of efficient capital use and asset management. The gross profit margin of 80.7% and operating margin of 38.0% further support the company's ability to maintain profitability in a competitive market.
Vytrus Biotech operates as a single-segment entity, with all revenue derived from its industrial services in environmental solutions. The company's geographic exposure is not disclosed in the available data, but its revenue concentration in a single business line suggests a focused operational strategy.
The company's growth trajectory is supported by its strong cash flow and profitability. While no specific revenue growth rates are provided, the company's operating cash flow and free cash flow suggest a stable and growing business. The capital expenditure of EUR -2.68 million indicates ongoing investment in infrastructure and operations.
Risk factors for Vytrus Biotech are minimal, with low liquidity and dilution risks identified. The company's debt-to-equity ratio of 0.12 suggests a conservative capital structure, and no immediate filing-based liquidity or dilution flags were detected. The company's dilution potential is also low, with no recent issuance or ATM/shelf disclosures indicating near-term pressure.
Recent events and filings for Vytrus Biotech do not show any material changes or risks. The company's financials remain stable, with no significant deviations in operating performance or capital structure.
- Vytrus Biotech maintains a strong liquidity position with a current ratio of 3.03 and EUR 1.5 million in cash and equivalents.
- The company's ROE of 28.1% and ROA of 19.75% indicate efficient capital and asset utilization.
- Vytrus Biotech operates as a single-segment entity focused on environmental services, with no disclosed geographic diversification.
- The company's capital structure is conservative, with a debt-to-equity ratio of 0.12 and low liquidity and dilution risks.
- Vytrus Biotech's operating cash flow of EUR 3.9 million and free cash flow of EUR 1.19 million support its growth and operational stability.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Vytrus Biotech SA Market data — financials · 2026-05-29